ADDICTION MEDICATION S.B. 403:
SUMMARY OF INTRODUCED BILL
IN COMMITTEE
Senate Bill 403 (as introduced 6-11-25)
ADDICTION MEDICATION S.B. 403:
SUMMARY OF INTRODUCED BILL
IN COMMITTEE
Senate Bill 403 (as introduced 6-11-25)
CONTENT
The bill would amend Part 73 (Manufacture, Distribution, and Dispensing) of the Public Health Code to require a pharmacist who received a lawful order from a prescriber for addiction medication to dispense the addiction medication without undue delay to the ultimate user. Also, the bill would require a pharmacy to have at least a two-week supply of addiction medication in stock at all times in the pharmacy.
"Addiction medication" would mean a controlled substance approved by the United States Food and Drug Administration for the treatment of an opioid use disorder, including buprenorphine.
"Undue delay" would mean a delay intended to obstruct a patient's access to the addiction medication or that is not a valid delay. "Valid delay" would mean a delay caused by fulfilling the requirements of Article 7 (Controlled Substances), Part 177 (Pharmacy Practice and Drug Control), or a rule promulgated under either, or any other delay commonly associated with the practice of pharmacy.
Proposed MCL 333.7333c Legislative Analyst: Alex Krabill
FISCAL IMPACT
The bill would have no fiscal impact on State or local government.
Fiscal Analysts: Ellyn Ackerman
Nathan Leaman
SAS\S2526\s403sa This analysis was prepared by nonpartisan Senate staff for use by the Senate in its deliberations and does not constitute an official statement of legislative intent. |